This information is intended for U.S. audiences only.

Intended for U.S. audiences only

Treat Today,
Defend Tomorrow.

toggle

You are leaving this site!

By clicking YES, you will be directed to another website. Click NO to remain on this page. Do you wish to continue to another website?

Corporate Headquarters
465 Route 17 South
Ramsey, NJ 07446
T: 201 478 5552
F: 201 478 5553

Florida Campus
ADMA Biologics
5800 Park of Commerce
Boulevard, NW
Boca Raton, FL 33487
USA
T: 561 989 5800
F: 561 989 5801

For General Inquiries, please contact:
Toll free: 800 458 4244, option 4
Email: CustomerService@admabio.com

For Medical Information, please contact:
Toll free: 800 458 4244, option 2
Email: MA@admabio.com

For adverse events reporting, please contact:
Toll free: 800 458 4244, option 2

Contact the FDA (MedWatch)
Toll free: 1-800-FDA-1088
Fax: 1-800-FDA-0178

Request Information

Please complete the form below, if you would like to receive further information on Nabi-HB® [Hepatitis B Immune Globulin (Human)].



We respect your privacy. Please read our Terms of Use and Privacy Statement for further information.

By clicking SUBMIT, you agree to be contacted by ADMA Biologics. You may opt out at any time.

Important Safety Information for Nabi-HB®

Individuals known to have had an anaphylactic or severe systemic reaction to human globulin should not receive Nabi-HB® [Hepatitis B Immune Globulin (Human)] or any other human immune globulin. Individuals who are deficient in IgA have the potential to develop antibodies against IgA and anaphylactic reactions.

In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, Nabi-HB should be given only if the expected benefits outweigh the potential risks.

Nabi-HB is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents (e.g., viruses) and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Nabi-HB [Hepatitis B Immune Globulin (Human)], must be administered only intramuscularly for post-exposure prophylaxis.

Vaccination with live virus vaccines (e.g., MMR) should be deferred until approximately three months after administration of Nabi-HB.

The most common adverse reactions associated with Nabi-HB in clinical trials were erythema and ache at the injection site as well as systemic reactions such as headache, myalgia, malaise, nausea and vomiting. No anaphylactic reactions with Nabi-HB have been reported.

Please see the full Prescribing Information for Nabi-HB [Hepatitis B Immune Globulin (Human)].

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.